The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC.
 
Joel Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals; Trumvira
Consulting or Advisory Role - Astellas Pharma; BeiGene; Bristol-Myers Squibb/Medarex; Galvanize Therapeutics; IgM Biosciences; MBQ Pharma; Taiho Pharmaceutical
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Amgen (Inst); Bold Therapeutics (Inst); Camurus (Inst); Cardiff Oncology (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neogene Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Regeneron (Inst); Revolution Medicines (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Xilio Therapeutics (Inst)
 
Diwakar Davar
Stock and Other Ownership Interests - mBiomics; Zola
Honoraria - ACM Biolabs; Clinical Care Options (CCO); Gerson Lehrman Group; Medical Learning Group; Merck; Xilio Therapeutics
Consulting or Advisory Role - ACM Bio; Ascendis Pharma; Clinical Care Options; Gerson Lehrman Group; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Abbvie; Adagene; Bayer; BMS; Delcath Systems; Eisai; Entos; Janssen Research & Development; Merck; Microbial Machines; Mirati Therapeutics; Nouscom; Pfizer; Roche/Genentech; Taiho Pharmaceutical; Tempus; Totus Medicines
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Nicholas DeVito
Employment - Duke University
Stock and Other Ownership Interests - Corvus Pharmaceuticals (I)
Honoraria - AlphaSights Consulting; Gerson Lehrman Group
Research Funding - Astellas Pharma (Inst); Merck; Xilio Therapeutics (Inst)
 
John Knecht
Stock and Other Ownership Interests - Becton Dickinson; Checkpoint Therapeutics; Fortress Biotech; Myovant Sciences; Reviva Pharmaceuticals
Honoraria - OMNI Health Media
Research Funding - Atossa Therapeutics; Cosmo Pharmaceuticals; EQRx; Phanes Therapeutics; Takeda; Xilio Therapeutics
 
Andrae Vandross
Employment - Next Oncology; Texas Oncology
Consulting or Advisory Role - Pliant Pharma
Research Funding - Abbvie (Inst); Ascentage Pharma (Inst); BiOneCure (Inst); Bolt Biotherapeutics (Inst); Chugai Pharma (Inst); Deciphera (Inst); Exelixis (Inst); Gilead Sciences (Inst); Immunomedics (Inst); IMPAC Medical Systems (Inst); Kirilys Therapeutics (Inst); Kura Oncology (Inst); Lyvgen Biopharma (Inst); MBRACE (Inst); Medikine (Inst); Nanjing (Inst); NGM Biopharmaceuticals (Inst); Nitto BioPharma (Inst); OncoResponse (Inst); Pliant (Inst); PMV Pharma (Inst); Sirnaomics (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Vividion Therapeutics (Inst); Xilio Therapeutics (Inst); Yufan Biotechnologies (Inst); ZielBio (Inst)
 
Cesar Perez
Consulting or Advisory Role - BeiGene; EMD Serono; Pfizer
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Artios (Inst); Ayala Pharmaceuticals (Inst); BeiGene (Inst); Coherent Biopharma (Inst); Compass Therapeutics (Inst); Corvus Pharmaceuticals (Inst); DualityBio (Inst); Elevation Oncology (Inst); Elpiscience (Inst); Genentech (Inst); Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Merus (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Tallac Therapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Alberto Bessudo
Research Funding - Xilio Therapeutics (Inst)
 
Anurag Gupta
Employment - Samyang Biopharm USA; Xilio Therapeutics
Stock and Other Ownership Interests - Thermo Fisher Scientific (I); Xilio Therapeutics
 
Ekta Patel
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - MustangBio; Xilio Therapeutics
Patents, Royalties, Other Intellectual Property - Patents, TCR2, Mustang Bio
 
Damiano Fantini
Employment - Merck (I); Xilio Therapeutics
Stock and Other Ownership Interests - Lilly; Merck (I); Xilio Therapeutics
 
Sattanathan Paramasivan
Employment - Selecta Biosciences; Xilio Therapeutics
Stock and Other Ownership Interests - ADMA Biologics; Allogene Therapeutics; Amylyx; AstraZeneca; Aurinia Pharmaceuticals; Avadel Pharmaceuticals; Avidity Biosciences; Baudax Bio; Biomarin; BridgeBio Pharma; Bristol Myers Squibb Foundation; Deciphera; Dicerna; Gritstone Bio; Iovance Biotherapeutics; Merck; Ocugen; PepGen; Pfizer; Roche; Sandoz; Selecta Biosciences; Takeda; VERA THERAPEUTICS; Xilio Therapeutics
 
David Crowe
Employment - Xilio Therapeutics
 
Meghan Duncan
No Relationships to Disclose
 
Scott McConnell
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
Katarina Luptakova
Employment - Xilio Therapeutics
Leadership - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
Aparna Parikh
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Checkmate Pharmaceuticals; CVS; Delcath Systems; Foundation Medicine; Guardant Health; Illumina; KAHR Medical; Pfizer; Pfizer; PMV Pharma (I); SAGA Diagnostics; Scarce; Seagen; Sirtex Medical; Taiho Oncology; Takeda; Takeda; UpToDate; Value Analytics Labs; Xilio Therapeutics
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Erasca, Inc; Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); PMV Pharma; PureTech (Inst); Syndax
Travel, Accommodations, Expenses - Karkinos Healthcare; Karkinos Healthcare
Other Relationship - C2i genomics; CADEX Genomics; Parithera; Xact Robotics